BIOMIRA RESEARCH (BIOM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOMIRA RESEARCH (BIOM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: chirodoc who wrote (67)	5/9/2000 10:51:00 AM
From: chirodoc	Read Replies (1) of 72

WALL STREET JOURNAL ARTICLE Biomira Gets Fast Track Status On Breast Cancer Vaccine Dow Jones Newswires EDMONTON -- The Food and Drug Administration granted fast track status on Biomira Inc.'s (BIOM) Theratope metastatic breast cancer vaccine. In a press release Monday, Biomira said Theratope was designated for the fast track program in studies as an adjunct to first line combination chemotherapy. The biotechnology company said earlier studies suggest Theratope offers "significant" survival benefits compared with standard treatments alone. Fast track programs are designed to facilitate the development and expedite review of drugs that treat unmet serious or life-threatening conditions. In one arm of two parallel prospectively randomized trials, vaccine-treated patients had a median survival of 26.5 months compared with 9.2 months in a retrospective control group. Biomira, which is evaluating the treatment in a Phase III trial with 900 evaluable patients, expects to complete enrollment by the end of the year. -Eamon Beltran; Dow Jones Newswires; 201-938-

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next